NF-kappaB in carcinoma therapy and prevention.
NF-kappaB in carcinoma therapy and prevention.
复制标题
DOI：
10.1517/14728222.12.9.1109
复制
发表时间：
2008-09
影响因子：
5.8
通讯作者：
Van Waes C
中科院分区：
文献类型：
--
作者：
Brown M;Cohen J;Arun P;Chen Z;Van Waes C
核因子-κB（NF-κB）是一个信号激活的转录因子家族，在正常情况下调节细胞对损伤和感染的反应，但在许多肿瘤中被异常激活。综述NF-κB B的活化及其在肿瘤发病机制中的作用，并探讨其作为肿瘤防治靶点的研究进展。从实验，流行病学，临床前研究和文献中引用的临床试验的证据进行了审查。越来越多的证据表明NF-κB参与了肿瘤发生、发展和转移过程中的细胞存活、炎症、血管生成、扩散和治疗抗性。抑制NF-κB的非特异性天然和合成药物在预防或治疗中表现出活性和安全性。NF-κB活化激酶和蛋白酶体作为肿瘤的靶向预防和治疗的研究正在进行中。
Nuclear factor-κB (NF-κB) includes a family of signal-activated transcription factors which normally regulate responses to injury and infection, but which are aberrantly activated in many carcinomas. To review the activation and role of NF-κB in pathogenesis and as a target for treatment and prevention in carcinoma. Evidence from experimental, epidemiologic, pre-clinical studies and clinical trials cited in the literature are reviewed. Cumulative evidence implicates NF-κB in cell survival, inflammation, angiogenesis, spread and therapeutic resistance during tumor development, progression and metastasis of carcinomas. Non-specific natural and synthetic agents that inhibit NF-κB have demonstrated activity and safety in prevention or therapy. NF-κB activating kinases and the proteasome are under investigation for targeted prevention and therapy of carcinoma.